| Outcome Measures: |
Primary: Left ventricular mass, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment | Secondary: Left ventricular mass index, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|LV end-systolic volume index, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|LV end-diastolic volume index, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|LA volume index, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|LV ejection fraction, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|Global longitudinal strain, As assessed by cardiac magnetic resonance imaging, performed on non-dialysis day, 24 weeks of treatment|LV end-systolic volume index, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|LV end-diastolic volume index, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|LA volume index, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|LV ejection fraction, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|Left ventricular mass index, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|Global longitudinal strain, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|LV relative wall thickness, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|Mitral early (E) and late (A) diastolic filling velocity ratio (E/A), As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|Mitral inflow deceleration time, As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|Tricuspid regurgitation peak gradient (TRPG), As assessed by echocardiography, performed on non-dialysis day, 12 weeks and 24 weeks of treatment|NT-proBNP, Blood tests obtained pre-dialysis session, 4 weeks, 12 weeks and 24 weeks of treatment|HbA1c, Blood tests obtained pre-dialysis session, 4 weeks, 12 weeks and 24 weeks of treatment|Lipid profile, Blood tests obtained pre-dialysis session, 4 weeks, 12 weeks and 24 weeks of treatment|KCCQ-OS, Performed on non-dialysis day, 12 weeks and 24 weeks of treatment|6-minute walking distance, Performed on non-dialysis day, 12 weeks and 24 weeks of treatment|3-minute heart rate variability, During hemodialysis session, 12 weeks and 24 weeks of treatment|Blood pressure, Obtained pre-dialysis session, 12 weeks and 24 weeks of treatment|Major adverse cardiovascular events (composite of CV death, myocardial infarction, stroke), By medical record confirmation and by interview, 24 weeks of treatment|Lower extremity non-traumatic amputation or revascularization, By medical record confirmation and by interview, 24 weeks of treatment|All-cause mortality, By medical record confirmation and by interview, 24 weeks of treatment|Hospitalization for heart failure, By medical record confirmation and by interview, 24 weeks of treatment|Hypoglycemic events, By medical record confirmation and by interview, 24 weeks of treatment|Hypokalemia, Blood tests obtained pre-dialysis session, 4 weeks, 12 weeks and 24 weeks of treatment|Diabetic ketoacidosis, By medical record confirmation and by interview, 24 weeks of treatment|Urinary tract infection, By medical record confirmation and by interview, 24 weeks of treatment|Genital tract infection, By medical record confirmation and by interview, 24 weeks of treatment
|
